BiotechTube

Icatibant + Placebo

Phase 3Recruiting
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Intradialytic Hypotension

Conditions

Intradialytic Hypotension

Trial Timeline

Dec 11, 2023 → Apr 1, 2026

NCT ID
NCT05834777

About Icatibant + Placebo

Icatibant + Placebo is a phase 3 stage product being developed by Pharvaris for Intradialytic Hypotension. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05834777. Target conditions include Intradialytic Hypotension.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05834777Phase 3Recruiting

Other Products from Pharvaris

Deucrictibant, PlaceboPhase 3
72
DeucrictibantPhase 3
72
Deucrictibant + PlaceboPhase 3
72
Deucrictibant + Placebo + Deucrictibant + Placebo + DeucrictibantPhase 3
72
deucrictibant + deucrictibantPhase 2/3
60